| Literature DB >> 28353655 |
Yoona Kim1, Jennifer B Keogh2, Peter M Clifton3.
Abstract
Epidemiological studies suggest that consumption of red and processed meat and refined grains are associated with type 2 diabetes and metabolic syndrome and increased inflammatory and fibrinolytic markers. We hypothesised that a diet high in red and processed meat and refined grains (HMD) would increase inflammatory markers and advanced glycation end products (AGEs) compared with a diet high in dairy, whole grains, nuts and legumes (HWD). We performed a randomised crossover study of two four-week interventions in 51 participants without type 2 diabetes (15 men and 36 women aged 35.1 ± 15.6 years; body mass index: 27.7 ± 6.9 kg/m²). No baseline measurements were performed. Plasma fluorescent AGEs, carboxymethyllysine, glucose, insulin, lipids, hs-CRP, interleukin 6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1) were analysed after four weeks on each diet. IL-6, hs-CRP, AGEs and carboxymethyllysine were not different between diets but PAI-1 was higher after the HMD than after HWD ((median and interquartile range) 158, 81 vs. 121, 53 ng/mL p < 0.001). PAI-1 on the HWD diet was inversely correlated with whole grains intake (p = 0.007). PAI-1 was inversely correlated with insulin sensitivity index (r = -0.45; p = 0.001) and positively correlated with serum total cholesterol (r = 0.35; p = 0.012) and serum triglyceride (r = 0.32; p = 0.021) on HMD. This trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12614000519651).Entities:
Keywords: advanced glycation products; dietary pattern; insulin sensitivity; plasminogen activator inhibitor type 1
Mesh:
Substances:
Year: 2017 PMID: 28353655 PMCID: PMC5409675 DOI: 10.3390/nu9040336
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Baseline characteristics of participants.
| Variable | All Participants 1 | Participants Who Completed LDIGIT ( | ||
|---|---|---|---|---|
| Insulin-Sensitive Group ( | Insulin-Resistant Group ( | |||
| Sex (M/F) | 15/36 | 9/15 | 6/19 | 0.3 † |
| Age (year) | 35.1 ± 15.6 | 35.5 ± 15.6 | 35.6 ± 16 | 1 |
| NGT ( | 17 | 10 | 6 | 0.2 |
| IFG/IGT ( | 34 | 14 | 19 | |
| Baseline fasting glucose (mmol/L) | 5.5 ± 0.7 | 5.3 ± 0.8 | 5.7 ± 0.6 | 0.07 |
| Baseline 2 h glucose (mmol/L) | 7.28 ± 1.6 | 6.96 ± 1.5 | 7.55 ± 1.7 | 0.2 |
| HOMA-IR (HWD) | 0.37, 0.43 | 0.29, 0.47 | 0.39, 0.5 | 0.07 ‡ |
| HOMA-IR (HMD) | 0.53, 0.66 | 0.21, 0.54 | 0.65, 0.8 | 0.01 ‡ |
| LDIGIT(120–150 min) insulin (HWD pmol/L) 2 | 33.4, 27.8 | 122.7, 149 | <0.001 # | |
| LDIGIT(120–150 min) insulin (HMD pmol/L) 2 | 29.6, 20.3 | 153, 180 | <0.001 # | |
| Baseline weight (kg) | 79.4 ± 21.36 | 69.7 ± 15.1 | 85.7 ± 21.7 | 0.005 |
| BMI (kg/m2) | 27.7 ± 6.9 | 24.4 ± 4.6 | 29.4 ± 5.9 | 0.002 |
| Baseline SBP (mmHg) | 112.2 ± 10.7 3 | 110.4 ± 9.2 4 | 114.3 ± 12.4 5 | 0.3 |
| Baseline DBP (mmHg) | 70.7 ± 9.7 3 | 69.1 ± 9.9 4 | 72.5 ± 9.5 5 | 0.3 |
| Total Fat Mass (kg) | 29 ± 15.7 | 20.6 ± 11.4 | 34.3 ± 13.3 | <0.001 |
| Total Lean Mass (kg) | 46.6 ± 11.5 | 45.4 ± 11.4 | 47.7 ± 12.1 | 0.5 |
| Total Fat Mass (%) | 36.6 ± 12.6 | 30.3 ± 12.8 | 41.0 ± 8.6 | 0.001 |
Groups were contrasted with an unpaired t-test. † p values were obtained by chi-square test. ‡ p values were obtained by Mann–Whitney nonparametric test. # p values were obtained by unpaired t-tests after log transformation. Values are means ± SDs except for HOMA-IR and LDIGIT(120–150 min) insulin, which are medians and interquartile ranges. The insulin-sensitive group and insulin-resistant group were defined a posteriori based on the insulin values of LDIGIT120–150 min, not from randomised groups: insulin-sensitive group <56 pmol/L with a median insulin of 33 pmol/L (n = 24) and insulin-resistant group >56 pmol/L with a median insulin of 122 pmol/L (n = 25). M, male; F, female; NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDIGIT, low-dose insulin and glucose infusion tests; HOMA-IR, homeostasis model assessment of insulin resistance; HWD, high in dairy, whole grains, nuts and legumes; HMD, high in red and processed meat and refined grains; SD, standard deviation. 1 n = 51; 2 n = 49, 3 n = 42; 4 n = 22; 5 n = 19.
Insulin sensitivity, lipids, inflammatory and fibrinolytic markers, and AGEs measured at the end of each dietary period in all participants (n = 51).
| Variable | HMD | HWD | |
|---|---|---|---|
| 5.3, 0.6 | 5.3, 0.5 | 0.9 | |
| 11.8, 15 | 9, 11 | 0.3 | |
| 0.53, 0.66 | 0.37, 0.43 | 0.25 | |
| 0.91, 0.72 | 0.86, 0.69 | 0.041 | |
| 1.39 ± 0.43 | 1.37 ± 0.42 | 0.4 | |
| 4.8 ± 1.0 | 4.6 ± 1.0 | 0.032 | |
| 1.01, 2.98 | 0.61, 2.55 | 0.7 | |
| 8, 12 | 8, 12 | 0.65 | |
| 158, 81 | 121, 53 | <0.001 | |
| 1388, 304 | 1370, 454 | 0.16 | |
| 1.37, 0.67 | 1.49, 0.56 | 0.07 |
p values (n = 51) for fluorescent AGEs, TG, CML, total cholesterol and HDL-C were determined by paired t-tests. Fluorescent AGEs, TG and CML were log transformed. p values (n = 51) for fasting glucose, fasting insulin, HOMA-IR, hs-CRP, PAI-1 and IL-6 were obtained from nonparametric tests. Values (n = 51) are expressed as medians and interquartile ranges except for HDL-C and total cholesterol, which are presented as means ± SDs. HMD, a high red and processed meat and refined grains diet; HWD, a high whole grain, nuts, dairy and legumes diet; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6; PAI-1, plasminogen activator inhibitor type 1; AGE, advanced glycation end product; CML, carboxymethyllysine.